OBJECTIVE: To study the association between prescribed antipsychotic drugs and outcome in schizophrenia or schizoaffective disorder in the community. DESIGN: Prospective cohort study using national central registers. SETTING: Community care in Finland. PARTICIPANTS: Nationwide cohort of 2230 consecutive adults hospitalised in Finland for the first time because of schizophrenia or schizoaffective disorder, January 1995 to December 2001. MAIN OUTCOME MEASURES: Rates of discontinuation of drugs (all causes), rates of rehospitalisation, and mortality associated with monotherapy with the 10 most commonly used antipsychotic drugs. Multivariate models and propensity score methods were used to adjust estimates of effectiveness. RESULTS: Initial use of clozapine (adjusted relative risk 0.17, 95% confidence interval 0.10 to 0.29), perphenazine depot (0.24, 0.13 to 0.47), and olanzapine (0.35, 0.18 to 0.71) were associated with the lowest rates of discontinuation for any reason when compared with oral haloperidol. During an average follow-up of 3.6 years, 4640 cases of rehospitalisation were recorded. Current use of perphenazine depot (0.32, 0.22 to 0.49), olanzapine (0.54, 0.41 to 0.71), and clozapine (0.64, 0.48 to 0.85) were associated with the lowest risk of rehospitalisation. Use of haloperidol was associated with a poor outcome among women. Mortality was markedly raised in patients not taking antipsychotics (12.3, 6.0 to 24.1) and the risk of suicide was high (37.4, 5.1 to 276). CONCLUSIONS: The effectiveness of first and second generation antipsychotics varies greatly in the community. Patients treated with perphenazine depot, clozapine, or olanzapine have a substantially lower risk of rehospitalisation or discontinuation (for any reason) of their initial treatment than do patients treated with haloperidol. Excess mortality is seen mostly in patients not using antipsychotic drugs.
OBJECTIVE: To study the association between prescribed antipsychotic drugs and outcome in schizophrenia or schizoaffective disorder in the community. DESIGN: Prospective cohort study using national central registers. SETTING: Community care in Finland. PARTICIPANTS: Nationwide cohort of 2230 consecutive adults hospitalised in Finland for the first time because of schizophrenia or schizoaffective disorder, January 1995 to December 2001. MAIN OUTCOME MEASURES: Rates of discontinuation of drugs (all causes), rates of rehospitalisation, and mortality associated with monotherapy with the 10 most commonly used antipsychotic drugs. Multivariate models and propensity score methods were used to adjust estimates of effectiveness. RESULTS: Initial use of clozapine (adjusted relative risk 0.17, 95% confidence interval 0.10 to 0.29), perphenazine depot (0.24, 0.13 to 0.47), and olanzapine (0.35, 0.18 to 0.71) were associated with the lowest rates of discontinuation for any reason when compared with oral haloperidol. During an average follow-up of 3.6 years, 4640 cases of rehospitalisation were recorded. Current use of perphenazine depot (0.32, 0.22 to 0.49), olanzapine (0.54, 0.41 to 0.71), and clozapine (0.64, 0.48 to 0.85) were associated with the lowest risk of rehospitalisation. Use of haloperidol was associated with a poor outcome among women. Mortality was markedly raised in patients not taking antipsychotics (12.3, 6.0 to 24.1) and the risk of suicide was high (37.4, 5.1 to 276). CONCLUSIONS: The effectiveness of first and second generation antipsychotics varies greatly in the community. Patients treated with perphenazine depot, clozapine, or olanzapine have a substantially lower risk of rehospitalisation or discontinuation (for any reason) of their initial treatment than do patients treated with haloperidol. Excess mortality is seen mostly in patients not using antipsychotic drugs.
Authors: M Isohanni; T Mäkikyrö; J Moring; P Räsänen; H Hakko; U Partanen; M Koiranen; P Jones Journal: Soc Psychiatry Psychiatr Epidemiol Date: 1997-07 Impact factor: 4.328
Authors: John M Kane; Barbara Cornblatt; Christoph U Correll; Terry Goldberg; Todd Lencz; Anil K Malhotra; Delbert Robinson; Philip Szeszko Journal: Schizophr Bull Date: 2011-11-18 Impact factor: 9.306
Authors: Rune A Kroken; Eirik Kjelby; Tore Wentzel-Larsen; Liv S Mellesdal; Hugo A Jørgensen; Erik Johnsen Journal: Ther Adv Psychopharmacol Date: 2014-12
Authors: Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll Journal: Schizophr Bull Date: 2012-12-17 Impact factor: 9.306
Authors: Helena Rantanen; Anna-Maija Koivisto; Raimo K R Salokangas; Mika Helminen; Hannu Oja; Sami Pirkola; Kristian Wahlbeck; Matti Joukamaa Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2008-07-28 Impact factor: 4.328